Summary Tamoxifen is currently established as the endocrine treatment of choice in breast cancer. In advanced breast cancer, response rates of up to 60% in women with oestrogen receptor (ER)-positive tumours have been reported. In early breast cancer, tamoxifen can produce significant benefits, both statistically and clinically, in terms of reduction in relative risk of relapse or death in all patient subgroups (i.e. ER status, aged < or > 50 years) except premenopausal women with ER-negative tumours. The major benefit, however, is seen in women over 50 years old with ER-positive tumours. The results of randomized trials suggest that the optimum duration of tamoxifen therapy is at least 5 years. Two large pragmatic trials (aTTom and ATLAS) are under way to determine whether additional benefit can be gained from continuing tamoxifen treatment beyond 5 years. Recent data also suggest possible synergism between tamoxifen and chemotherapy in the treatment of early breast cancer in post-menopausal women. Other benefits of tamoxifen treatment include reduction in the risk of developing contralateral breast cancer. Included among the non-breast cancer benefits of tamoxifen are reduced risk of cardiovascular disease and protection against bone loss in post-menopausal women. These benefits must be weighed against the possible increased incidence of endometrial cancer. Notwithstanding its undoubted success, there is a need for agents to improve upon tamoxifen. Newer agents, such as the luteinizing hormone-releasing hormone analogue goserelin and the new-generation aromatase inhibitors, such as anastrozole, will add new life to the search for an improved endocrine therapy for early breast cancer.
Tamoxifen therapy has undoubtedly been one of the greatest success stories in the pharmacological management of breast cancer. Tamoxifen's value for this indication was discovered almost accidentally about 30 years ago, and in the early 1970s the drug was soon established as the treatment of choice for postmenopausal women with breast cancer, replacing the then conventional treatment with diethylstiboestrol. Tamoxifen has a good tolerability profile, and serious side-effects are rare. The most common adverse events reported are hot flushes, vaginal discharge, irregular menses and endometrial changes. Less common adverse events include tumour flare, visual disturbances, leucopenia, ovarian cysts in premenopausal women and liver enzyme abnormalities. Despite this, withdrawal from tamoxifen treatment because of adverse events is below 5% in most patient series.
Using conventional Union Intemationale Contre Cancer (UICC) criteria, tamoxifen produces an objective remission rate of about 30% in unselected cases of advanced breast cancer. If, however, stable disease is accepted as a useful clinical end point and patients with visceral disease or oestrogen receptor (ER)-negative disease are excluded, the useful response rate rises to about 60%. The median duration of response in these cases is about 2 years, but eventually all patients will relapse and die (Jaiyesimi et al, 1995; Baum, 1997; Powles, 1997) . Tamoxifen gives comparable response rates to other endocrine modalities (Table 1) (Rose and Mouridsen, 1988) . In view of its side-effect profile in comparison with these other agents (Muss, 1992) , it is easy to understand why tamoxifen was so rapidly accepted when it was introduced for the management of advanced breast cancer. 
Current status
The benefit of tamoxifen as adjuvant therapy after the surgical treatment of early breast cancer is of even greater importance than its benefit in advanced disease. The first trials for adjuvant therapy were started in the late 1970s and the results were reported in the early 1980s. Originally, the control groups were given no adjuvant therapy and the treated groups received either 1 or 2 years of tamoxifen treatment. The first trial to demonstrate a survival advantage with adjuvant tamoxifen was the Nolvadex Adjuvant Trial Organisation (NATO) study, published in 1983 (Nolvadex Adjuvant Trial Organisation, 1983 . Within a short time other studies demonstrated a survival advantage with tamoxifen prescribed for 2-5 years after surgery, and a meta-analysis of adjuvant tamoxifen trials conducted in 1990 demonstrated unequivocally that adjuvant tamoxifen was associated with relative-risk reductions for relapse and death of 25% and 17%, respectively, over a 10-year period (Early Breast Cancer Trialists' Collaborative Group, 1992) .
In the last decade, knowledge of adjuvant tamoxifen has been refined. The 1990 overview, published in 1992, showed that the groups most likely to benefit were post-menopausal women with ER-positive tumours, in whom up to 12% absolute improvement in 10-year survival can be expected (Early Breast Cancer Trialists' Collaborative Group, 1992) . However, post-menopausal women with ER-negative tumours and premenopausal women with ERpositive tumours were also seen to benefit (Early Breast Cancer Trialists' Collaborative Group, 1992) .
The current status of tamoxifen in adjuvant therapy has been confirmed following the 15-year world overview conducted in 
Duration of tamoxifen therapy
The optimum duration of tamoxifen therapy is still undetermined, although more data have become available in recent years. It is clear that 2 years of therapy is suboptimal, and that the optimum duration may be at least 5 years. Based on current data, however, 5 years of tamoxifen can be considered a good standard of treatment (Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group, 1996; Fisher et al, 1996; Swedish Breast Cancer Cooperative Group, 1996) . The Swedish Breast Cancer Cooperative Group trial enrolled over 1700 patients in each treatment arm, and compared 2 and 5 years of tamoxifen therapy with a follow-up to 10 years (Swedish Breast Cancer Cooperative Group, 1996) . A highly significant difference in event-free survival at 10 years was found, and a just significant improvement in overall survival at 10 years for 5 years versus 2 years of treatment ( Figure 1 ). The Cancer Research Campaign Breast Cancer Trials Group also enrolled large numbers of patients (over 1400 in each treatment arm). It found a significant advantage for 5 years of tamoxifen therapy over 2 years in terms of event-free survival to 6 years, but no significant difference in overall survival ( Figure 2 ) (Current Trials Working Party of the Cancer Research Campaign Breast Cancer Trials Group, 1996) . The results in these two data sets might seem slightly disappointing, but it must be remembered that not all the patients in the 5-year arms of these studies received tamoxifen for 5 years. The advantage may become more apparent with longer follow-up and more patients in the 5-year arm. Other studies have suggested that 5 years may be the optimum duration of treatment (Fisher et al, 1996) .
Much uncertainty still remains concerning the optimum duration of Tamoxifen Treatment. Two large-scale trials, aTTom (adjuvant Tamoxifen Treatment offer more?) and ATLAS (Adjuvant Tamoxifen -Longer Against Shorter), have been designed to address this problem (Peto, 1996) . The aTTom trial has a simple and pragmatic design. After at least 2 years of relapse-free adjuvant tamoxifen therapy, the uncertainty principle applies: if further tamoxifen is indicated, the patient is not eligible for inclusion in the trial, whereas if it is uncertain whether the drug should be continued the patient is randomized either to stop tamoxifen treatment or to continue it for at least 3 years. The ATLAS trial has a similar design. Again, the patients enrolled had received at least 2 years of relapse-free adjuvant tamoxifen therapy. The uncertainty principle also applies in this trial: if there is uncertainty as to whether tamoxifen should be continued, the patient is randomized either to stop tamoxifen or to continue the drug for at least 5 years. It is hoped that the results of these pragmatic trials with large numbers of patients will define the optimum duration of the drug.
Synergism between tamoxifen and chemotherapy
Recent data suggest that some degree of synergism may be achieved between tamoxifen and chemotherapy, which may further improve the response to treatment in selected cases (Tormey et al, 1996) . Disease-free survival and overall survival at 5 years were compared in patients with ER-positive breast cancer receiving tamoxifen alone, tamoxifen plus methotrexate and 5-fluorouracil (MF), or tamoxifen plus cyclophosphamide and MF (CMF) (Fisher et al, 1997) . The disease-free survival rate at 5 years was 90% in the tamoxifen plus CMF group -significantly better (P < 0.01) than that with tamoxifen alone (84%) ( Group, 1992) . The 1995 world overview confirms this benefit (Early Breast Cancer Trialists Collaborative Group, 1998) . Based on these data, large-scale trials are in progress in Europe and North America for the prevention of breast cancer in women judged to be at high risk.
Beneficial and harmful side-effects of tamoxifen Considerable research effort is throwing light on the mechanisms of response to and resistance to tamoxifen, which can no longer be considered simply as an anti-oestrogen. In fact, the drug's agonist properties may be responsible for some of its unanticipated benefits and potential adverse effects.
British Journal of Cancer (1998) Group, 1996) As an attenuated oestrogen, tamoxifen appears to protect the myocardium, and to reduce the incidence of ischaemic heart disease (Dewar et al, 1992; Love et al, 1994a ) and the anticipated loss of bone mineral density in post-menopausal women (Love et al, 1992; Powles et al, 1996) . Tamoxifen has been used in the treatment of mastalgia (Bahamonde et al, 1997; Fentiman et al, 1988) , and beneficial effects on lipids (Love et al, 1994b; Bilimoria et al, 1996) have been demonstrated. At the same time, the agonist properties of tamoxifen are thought to be partly responsible for its limited usefulness as an anti-oestrogen. There is some evidence that experimental clones of breast cancer cells develop a dependence on tamoxifen. Theoretically, the late failure of, or de novo resistance to, adjuvant tamoxifen might be related to these observations (DeFriend and Howell, 1994; Katzenellenbogen et al, 1997) .
Tamoxifen has also been implicated in the increased incidence of endometrial cancers that has been observed in some of the clinical trials and reported in the meta-analysis (Assikis et al, 1996; MacMahon, 1997) . This relationship has not been observed in British trials, however, and an ascertainment bias cannot be excluded, as patients receiving tamoxifen are screened more intensively for uterine abnormalities than those in the control groups. For example, the gynaecological symptoms caused by tamoxifen are often investigated by transvaginal ultrasonography, and endometrial thickening is commonly reported. Biologically, the ultrasonographic image does not always reflect endometrial thickening, but commonly subendometrial cystic degeneration and oedema. As a result, hysteroscopy is often performed, which might detect latent endometrial cancer -in situ latent disease that would not have been found if the woman had not had tamoxifen-induced gynaecological symptoms. Furthermore, the one published study on endometrial cancer screening in the normal population of women in the USA (Koss et al, 1984) showed a prevalence not dissimilar to that observed in a tamoxifen-treated group (Fisher et al, 1994) .
Some worries have also been voiced about reports of crystalline retinal deposits and other ocular toxicities. However, data from prospective studies including the large adjuvant therapy trials British Journal of Cancer (1998) Since 1985, an overall reduction in breast cancer mortality has tamoxifen (TAM) over TAM alone in node-negative patients with estrogentaken place in the UK (Quinn and Allen, 1995 (LHRH) limitations and possible adverse effects have been described above, analogue goserelin with or without tamoxifen in pre-and perimenopausal It is possible that the luteinizing hormone-releasing hormone patients with advanced breast cancer. Eur J Cancer 31A: [137] [138] [139] [140] [141] [142] analogue, goserelin (Jonat et al, 1995) 
